#Western-Biotech

[healthlineonline]

Buy Somastim Online is a Highly Effective Sports Medicine

The Somastim medicine is highly effective for sports, and seasoned athletes know that growth hormones can prolong life and heal different diseases. Human growth hormone is also essential for the growth of the human body and is produced in the anterior lobe present in the pituitary gland. Somatropin is sold for sale and used to develop leaner muscle growth in kids and adolescents. Adults buy Somastim online to improve essential functions in their bodies. However, it does not help them to achieve additional bone growth; nevertheless, the properties of this medicine help control better protein metabolism in the body. For more details click:

https://sciroxxonline.com/buy-hgh-igf1-and-other-peptides-including-usa-local-delivery/51-somastim-pharma-grade-somatropin.html

[assay-biotechnology]

Phosphorylation

Phosphorylation is a key reaction where a phospho group (PO4) is added to protein via enzymatic processes. This allows for protein modification that is central in cell signaling, cellular regulation, cell adhesion, and many more important cellular processes. Phospho protein modification predominantly occurs on amino groups: serine, threonine, and tyrosine. These modified groups on proteins are the focus of post translational modifications. Assay Biotechnology is proud to provide antibodies that are specific for these phosphorylated proteins.

Read more

[soraka-in-warhammer40k]

I'm always fascinated when someone at the club rants about "how they just invented T'au to cash on them anime weebs", completly oblivious to the time and culture of their creation. So T'au came out first in 2001, and were obviously conceptualized some years prior, which puts them into the late 90s in their original design. This is slowly hitting "the majority of the populance has no relevant internet access whatsoever" levels of "barbaric analog ages".

So imagine where GW sits in the late 90s - its a small studio somewhere in England barely coming to touch with the first elements of the internet, with the most dominant medium being television which... is not really about "exotic" shows from the other end of the world? Those get ported over when they have proven to be a hit in their own country mostly.

And without the internet as we know it today, the anime community just... did not exist. You have to understand that the whole concept of online anime culture centred around piracy, fansubs, fanart, and the creation of the term "weeabo" was a mid-to-late 00s thing, and it took almost another decade before "weeb" was somewhat reclaimed and no longer an online-slur.

There was a whole generation that grew up with (often horribly localized) japanese shows on TV (Pokemon, Dragon Ball, Sailor Moon) which came over with some delay to their release in Japan. By the time this generation came to congregate into online spaces and form any sort of fan-identity and culture, the T'au and their battlesuits had already been a design over a decade old.

"But wait isn't Gundam from the 70s"? Yes, that is totally correct. However, this is the one glaring mistake people make: you cannot compare modern day media content circulation around the globe to the analog ages. Those of us who remember these barbaric analog times know how it was: you just did not know stuff existed. If it was not in the newspaper or on the telly, it might as well not exist unless you knew a guy who knew a guy who knew a guy.

Sure, the Internet was slowly becoming a thing that found widespread use, but it would still take a while - not to mention the technical limitations. No streaming episodes. You start the download (if you can find someone who hosted the file of a series you had to know even existed first) somewhere around lunch, to hopefully get something to watch in the afternoon. Oh and also that blocked the household's phone-line and if the download cancelled for whatever reason then it was back to square one. Under such conditions, the online community we know today could simply not exist, as the alternative was importing stuff from the other end of the world for quite the money, or hoping a really shoddy localized VCR-tape ended up at your Blockbuster-equivalent.

Of course there was anime before that time, even those regarded absolute classics in the west, but those mostly achieved that rank over here in retrospective. When in the late 00s people wanted to watch stuff and had the ability to do so they shared what was considered "the classics" first (shared to the best of their ability with one episode cut into 5 parts on youtube with sometimes very questionable subtitles).

So even if we assume there was someone at GW in the 90s who was a total "proto-weeb" and Gudam-fan, there was literally no reason to "make knock-off Gundams" because the miniscule western wargaming audience SIMPLY DID NOT KNOW THE STUFF.

You can't make a marketing ploy to reference something your average consumers have never heard off. If anything, the creation of the T'au as a robotic-centred faction was inevitable: they needed a design that could hold their own in the setting, but Necrons hogged the full-robot niche, Imperials were weird cyborgs, Orks the "madman-scrap-tech", and Nids the "biotech". The only thing left here was "not full robot but also very clean and efficient" - and just like that, the Battlesuits and Drones were born.

It was only in later years when the Internet had come into full swing where they decided to go full-suit with releases such as the Riptide, but if we talk about the OG design of T'au and the first decade? Nothing to do with anime or "fishing for weebs". The fish would not be coming to that spot for almost a decade, and it would take a bit more before their numbers were plentyful enough to make it worth casting a line out.

[afeelgoodblog]

The Best News of Last Week - March 13, 2023

🐝 - Did you hear about the honeybee vaccine? It's creating quite the buzz! But seriously, it's a major breakthrough in the fight against American foulbrood and could save billions of bees.

1. Transgender health care is now protected in Minnesota

Minnesota Governor Tim Walz signed an executive order protecting and supporting access to gender-affirming health care for LGBTQ people in the state, amidst Republican-backed efforts across the country to limit transgender health care. The order upholds the essential values of One Minnesota where all people, including members of the LGBTQIA+ community, are safe, celebrated, and able to live lives full of dignity and joy.

Numerous medical organizations have said that access to gender-affirming care is essential to the health and wellness of gender diverse people, while states like Tennessee, Arizona, Utah, Arkansas, Alabama, Mississippi, South Dakota, and Florida have passed policies or laws restricting transgender health care.

2. First vaccine for honeybees could save billions

The US government has approved the world's first honeybee vaccine to fight against American foulbrood, a bacterial disease that destroys bee colonies vital for crop pollination.

Developed by biotech company Dalan Animal Health, the vaccine integrates some of the foulbrood bacteria into royal jelly, which is then fed to the queen by the worker bees, resulting in the growing bee larvae developing immunity to foulbrood. The vaccine aims to limit the damage caused by the infectious disease, for which there is currently no cure, and promote the development of vaccines for other diseases affecting bees.

3. Teens rescued after days stranded in California snowstorm: "We were already convinced we were going to die"

The recent snowstorms in California have resulted in dangerous conditions for hikers and residents in mountain communities. Two teenage hikers were rescued by the San Bernardino County sheriff's department after getting lost in the mountains for 10 days.

The boys were well-prepared for the hike but were not prepared for the massive amounts of snow that followed. They were lucky to survive, suffering from hypothermia and having to huddle together for three nights to stay warm.

Yosemite National Park has had to be closed indefinitely due to the excessive snowfall.

4. La Niña, which worsens Atlantic hurricanes and Western droughts, is gone

The La Nina weather phenomenon, which increases Atlantic hurricane activity and worsens western drought, has ended after three years, according to the National Oceanic and Atmospheric Administration. That's usually good news for the United States and other parts of the world, including drought-stricken northeast Africa, scientists said.

The globe is now in what's considered a "neutral" condition.

5. Where there's gender equality, people tend to live longer

Both women and men are likely to live longer when a country makes strides towards gender equality, according to a new global study that authors believe to be the first of its kind.

The study was published in the journal PLOS Global Public Health this week. It adds to a growing body of research showing that advances in women's rights benefit everyone. "Globally, greater gender equality is associated with longer [life expectancy] for both women and men and a widening of the gender gap in [life expectancy]," they conclude.

6. New data shows 1 in 7 cars sold globally is an EV, and combustion engine car sales have decreased by 25% since 2017

Electric vehicles are the key technology to decarbonise road transport, a sector that accounts for 16% of global emissions. Compared with 2020, sales nearly doubled to 6.6 million (a sales share of nearly 9%), bringing the total number of electric cars on the road to 16.5 million.

Sales were highest in China, where they tripled relative to 2020 to 3.3 million after several years of relative stagnation, and in Europe, where they increased by two-thirds year-on-year to 2.3 million. Together, China and Europe accounted for more than 85% of global electric car sales in 2021

7. Lastly, watch this touching moment as rescued puppy gains trust in her new owners

By the way, this is my newly started YouTube channel. Subscribe for more wholesome videos :D

---

That's it for this week. If you liked this post you can support this newsletter with a small kofi donation:

Buy me a coffee ❤️

Let's carry the positivity into next week and keep spreading the good news!

[hartshorn-and-isinglass]

If you've ever wondered how biotech companies advertise, there are of course the usual routes like trade magazines and such, but for a brief blessed moment just over a decade ago, several companies were persuaded to try and go viral with music videos:

This Eppendorf commercial is still living rent-free in my head:

Bio-Rad really got into hyping their PCR products:

Literally no one has ever been this excited about Western blots, I promise.

Honorable mention to ABI (now part of Thermo Fisher) for the Dancing Scientist commercial:

(ETA: oh wow, TMO actually edited the Dancing Scientist out of this ad so I had to go hunt for the original. Should be fixed now.)

Do with this information what you will.

[msclaritea]

This article is from 2019 and never more important than now. Maybe people didn't take it seriously then. I hope they will, now.

"Shortly after World War II, when Europe lay in ruin and humanity was newly traumatized by the spectacle of organized violence that an authoritarian regime could achieve in the industrial epoch, the Western World experienced a sudden cultural shift. This new regime of thought is sometimes called postmodernism, but that term is obscure and overused; a better way to think about this is that there was no longer a unifying narrative, a guiding thread that united humans in the West. Whereas some countries might have previously had religious bonds, or ethnic bonds, or monarchial bonds, or even political bonds around, say, an authoritarian leader, suddenly there were none anymore — or at least none that were universally believed. Individualism and identity were more important, and politicians and legal bodies would now have to consider how to govern subjects in an ambiguous, pluralistic, multicultural world.

At the same time, it was becoming clear that the forces that shaped the world — the power to  organize society, or to exterminate it — were in the hands of scientists and technologists. The atom bomb, the intercontinental ballistic missile, the radio, the car, electrification, the refrigerator and the moon landing all happened in a span of about a hundred years. Science and technology spurred World War II, and led to its conclusion. And as the war receded from memory, it was apparent that the areas of greatest economic growth were all in technical fields — computers, engineering, communications, biotech and material science.

Jean-Francois Lyotard, a French philosopher who studied the condition of knowledge in this new era, realized that technology had changed the way that humans even thought about what knowledge was. Knowledge that computers could not process or manage — for instance, the ability to think critically or analyze qualitatively — was increasingly devalued, while the kinds of knowledge that computers could process became more important. As Lyotard wrote:

The miniaturisation and commercialisation of machines is already changing the way in which learning is acquired, classified, made available, and exploited....The nature of knowledge cannot survive unchanged within this context of general transformation. It can fit into the new channels, and become operational, only if learning is translated into quantities of information. We can predict that anything in the constituted body of knowledge that is not translatable in this way will be abandoned... Along with the hegemony of computers comes a certain logic, and therefore a certain set of prescriptions determining which statements are accepted as “knowledge” statements.

Lyotard wrote this in 1978, before the modern internet even existed. Today, the idea that computational forms of knowledge — and/or the kinds of people who traffic in that knowledge — are more valuable to our society seems to be universal. Thanks to generous grants from the tech industry and well-heeled nonprofits like the Mellon Foundation, humanities academics across the world have been spurred to do more research in what is called the "digital humanities" — a vague term that often means applying statistical and quantitative tools to data sets that involved humanities research, such as literary corpuses. The tech industry investments in digital humanities fulfills Lyotard's prophecy that society would cease to see the humanities' brand of knowledge as useful; that it would attempt remake the humanities into a discipline characterized by discrete information, rather than a means of analyzing, considering, and philosophizing the world.

In the same essay, Lyotard actually distinguishes between two different types of knowledge: the "positivist" kind, that is applicable to technology; and the "hermenutic" kind of knowledge. Hermeneutics, meaning the study of interpretation, is what the humanities (and to some extent social sciences) concerns itself with. One can see how this kind of knowledge might be difficult for computers to catalogue and use. The idea that a computer could produce a literary analysis of a Vonnegut short story sounds absurd because it is: this is not the way that computers process data, this is not what humans generally regard computers as useful for, and it is certainly not what they are designed to do by the tech companies. Unsurprisingly, then, this type of humanities knowledge has become devalued, and not even considered "knowledge" by many.

So this leads us to a predicament in which slowly, since the postwar era, humanities skills and associated knowledge have been devalued, while STEM knowledge — an acronym for "Science, Tech, Engineering and Math," meaning the kind of quantitative knowledge associated with technology — reigns supreme. One of the most interesting places that you can see this trend is in fiction: the kinds of heroes and protagonists that people admire and look up to in fiction are increasingly those with STEM knowledge, as these people are seen as heroes because we uncritically accept that STEM knowledge is what changes the world. There is a reason that Iron Man is a billionaire technologist, and Batman is a billionaire technologist, and The Hulk's namesake Bruce Banner has multiple PhDs in the Marvel canon, and that the mad scientist Rick Sanchez (of "Rick and Morty") is essentially an immortal, infinitely powerful being because of his ability to understand science and wield technology. We admire these people because they possess the kinds of skills that our society deems the most valuable, and we're told that we, like them, can use these skills to master the universe.

(There is a potent irony here, of course, in that it is artists who write these narratives, and artists who are partly responsible for creating and popularizing this kind of STEM-supremacist propaganda. Weirdly, though, you rarely see a superhero or a super-spy who started life as a painter, or a novelist, or a comic book artist.)

Moreover, in real life, people who possess technological knowledge, primarily the scions of Silicon Valley, are widely adulated, viewed as heroes who will inherently change society for the better. This manifests itself in various ways: some technologists, like Bill Gates and Mark Zuckerberg have set up philanthropic foundations to "solve" our social problems — though curiously, the means by which that happens always seems to enrich themselves and their fellow capitalists along the way. Some of them promise widespread social change for the better via their own businesses, as though running a for-profit tech company was in and of itself a gift to the world and a net positive for social cohesion: you see this in many tech companies that advertise themselves as operating "for good," such as in the PR rhetoric of Facebook.  Then, there are those who believe that their contribution to society will be helping us leave this planet, and who are investing heavily in private spaceflight companies with the ultimate intention of colonizing space; this includes both Elon Musk and Jeff Bezos.

In all these cases, the idea that people with STEM knowledge are predestined to save the world is an idea has become so dominant we don’t even question it. Some call this attitude STEM chauvinism, though I prefer the moniker STEM Supremacy. The noun "supremacy," I believe, is called for, because of how the idea that STEM knowledge (and those who posses it) is superior to other forms of knowledge has become so hegemonic that our culture openly mocks those who possess other forms of knowledge — particularly the hermeneutic, humanities-type knowledge. There is a fount of memes about humanities majors and how useless their fields are; some of these memes depict humanities majors as graduating to working at low-wage jobs like McDonalds; others mock critical humanities majors (particularly gender studies) as being out-of-touch, social failures.

Such discourse is intersectional with other supremacist beliefs, such as patriarchy, and often these kinds of memes that celebrate STEM knowledge and mock humanities knowledge will simultaneously mock women and celebrate masculinity. It was unsurprising to me when, last year, it leaked that a Google engineer, James Damore, had circulated an anti-diversity manifesto in which he used discredited science to argue that there were biological reasons for the gender gap. He went on to argue that there were reasons men were more interested in computers and in leadership, and women less. Though Damore was fired, he maintains that many of his peers agreed with him. Such incidents speak to the ways that different chauvinist tendencies, one of STEM Supremacy and one of patriarchy, can intersect to form novel noxious political ideologies.

The concept of "STEM Supremacy" relies on a popular belief that STEM knowledge is synonymous with progress. Yet if you take this kind of belief a bit too far, you might be keen to abandon democratic ideals and start to believe that we really should live in a society in which the STEM nerds rule over us. This has resulted in a number of half-baked supremacists within the tech industry who advocate either for authoritarian technocracies or, more bizarrely, monarchy.

I’ll give a few brief examples. There’s Google engineer Justine Tunney, a former Occupy Wall Street activist who now calls for “open-source authoritarianism. ” Tunney has argued against democracy and in favor of a monarchy run by technologists, and advocated for the United States to bring back indentured servitude.

But perhaps best-known among the techno-monarchists is Mencius Moldbug, the nom de plume of Curtis Yarvin, a programmer and founder of startup Tlon — a startup that is backed at least in part by billionaire anti-democracy libertarian Peter Thiel, who famously once wrote he did not believe democracy and freedom were compatible, and expressed skepticism over women's suffrage. Moldbug's polemics are circular, semi-comprehensible, and blur political theory and pop culture; Corey Pein of The Baffler described his treatises as "archaic [and] grandiose," while being "heavily informed by the works of J.R.R. Tolkien and George Lucas."

Both of these so-called thinkers constitute parts of a larger movement that calls itself "Dark Enlightenment," alternatingly known as "neoreactionaries." True to its name,  the political agenda of Dark Enlightenment includes a celebration of patriarchy, monarchy, and racialized theories of intelligence differentials. 

The notion that monarchy is popular again in Silicon Valley might sound absurd. We associate monarchies with stodgy, quaint medieval kingdoms, the opposite of the disruptive, fast-moving tech industry. And yet those in the tech industry who see monarchy as appealing are keen to point out how the hierarchical aspects of monarchial rule are actually familiar to their industry. As Pein mentions in his Baffler essay, Thiel delivered a lecture in 2012 in which he explained the connection:

A startup is basically structured as a monarchy. We don’t call it that, of course. That would seem weirdly outdated, and anything that’s not democracy makes people uncomfortable.

[But] it is certainly not representative governance. People don’t vote on things. Once a startup becomes a mature company, it may gravitate toward being more of a constitutional republic. There is a board that theoretically votes on behalf of all the shareholders. But in practice, even in those cases it ends up somewhere between constitutional republic and monarchy. Early on, it’s straight monarchy. Importantly, it isn’t an absolute dictatorship. No founder or CEO has absolute power. It’s more like the archaic feudal structure. People vest the top person with all sorts of power and ability, and then blame them if and when things go wrong.

[T]he truth is that startups and founders lean toward the dictatorial side because that structure works better for startups. It is more tyrant than mob because it should be. In some sense, startups can’t be democracies because none are. None are because it doesn’t work. If you try to submit everything to voting processes when you’re trying to do something new, you end up with bad, lowest common denominator type results.

The underpinnings of STEM Supremacy are, as I've laid out, complicated to see and stretch back to the end of World War II — but when put together they form a broader picture of where the philosopher-kings of the tech industry are heading, and what they believe. If we continue to live in a society that devalues humanities-type knowledge and glorifies STEM knowledge, this kind of thinking will persist, I fear. And the tech industry is partly responsible for cultivating this noxious worldview, in the sense that their PR apparatuses glorify STEM knowledge and encourage the public to view their leaders as demigods.

This isn't a unique phenomenon. Any situation where a certain ideology is denigrated and another valorized, there will be at some point a corresponding rise in a chauvinism in favor of the valorized ideology. The situation today is made more complicated by the fact that the tech industry benefits from the normalization of STEM Supremacist beliefs. The unearned trust that the public has for tech startups and tech industry ideas, the lack of regulation, and the absurd valuations of companies that continue to lose money — this is all motivated by an underlying belief that these companies are innately good, their owners smart, and their work more vital than other fields. Whether they admit it or not, you can draw a line from the public relations departments of tech companies and Justine Tunney's call for "open-source authoritarianism."

Ironically, the only antidote to all this sophistry is the humanities — the kind of critical thinking that they entail, and the kind of thinking that it is impossible for computers to do. I've often wondered if part of the tech industry's investment in digital humanities is designed to help stave off critical discourse or criticism of their companies. Indeed, by remapping the idea of what knowledge is in the first place, the tech industry is helping to realize a future in which we lack even the language to think critically about their role in society. Or maybe even a future in which they rule over us as monarchial, benevolent dictators — at least in their eyes. Perhaps this was the plan all along. (Oh yeah. It was)

By KEITH A. SPENCER

Keith A. Spencer is a senior editor at Salon who edits Salon's science/health vertical. His book, "A People's History of Silicon Valley: How the Tech Industry Exploits Workers, Erodes Privacy and Undermines Democracy," was released in 2018. Follow him on Twitter at @keithspencer, or on Facebook here.

_______________________________________________

THESE FUCKERS IN SILICON VALLEY WANT A MONARCHY !!

"Few Catholics outside the D.C area are likely familiar with Fr. Arne, who never wrote a book or made national headlines. Yet a list of those who appear in Eberstadt’s book to laud his role among “billionaires and Supreme Court Justices” indicates the breadth of his influence: George Weigel, Fr. Thomas Joseph White, Arthur Brooks, Hadley Arkes, Peter Thiel, and Fr. Paul Scalia, to name but a few..."

"From his perch on K Street at the Catholic Information Center (CIC), Father Arne Panula shepherded some of the nation’s power brokers into the Catholic Church..." Mary Eberstadt

“As recently as 2017, Billy [Barr] was on the board of directors of the DC-based Catholic Information Center, led by the ultraright and secretive group Opus Dei…Its board includes the Federalist Society’s Leonard Leo, and White House counsel Pat Cipollone..."

*Above thread is chockful of more information!*

[wildmonkeysects]

Routine Infant Circumcision harms

The American Elephant in the Hospital.

In the EU, the rate of infant fatalities from infant circumcision is zero.

In the USA, regulatory agencies ignore multiple harmful complications of routine infant circumcision including fatality, and chase down one premmie infant fatality from mis-applied probiotics.

Could it be because non-consenting amputation of essential erogenous tissue is a billion dollar business in America, providing royalty free neo-natal tissue containing fibroblasts and stem cells to biotech while generating cash flow by charging for the optional cosmetic "procedure"?

[gusty-wind]

BioNTech Faces Lawsuit Over COVID-19 Vaccine Side Effects

In a landmark development, BioNTech SE, the German biotechnology company that partnered with Pfizer Inc. to produce one of the first COVID-19 vaccines, is now facing its first legal challenge in Germany over vaccine side effects.

In an unprecedented case that could potentially spark hundreds of similar claims across Germany, the plaintiff – a woman who has chosen to remain anonymous due to Germany’s privacy laws – is suing BioNTech for a minimum of €150,000 ($161,500) in damages.

According to Reuters, she cites “damages for bodily harm as well as compensation for unspecified material damage,” as detailed by Hamburg’s regional court and the law firm representing her, Rogert & Ulbrich.

Side effects listed in the suit include upper-body pain, swollen extremities, fatigue, and sleeping disorders attributed to the BioNTech Pfizer vaccine.

The landmark case’s first hearing will take place on Monday.

Conservatives Are Looking For Ways To Boycott and Move Spending Away From Woke Corporations -- Here Is One Way To Do It

More lawsuits are coming in Germany. Rogert & Ulbrich reports filing about 250 cases for clients seeking damages for COVID-19 vaccine side effects. Another law firm, Caesar-Preller, claims to represent 100 cases, collectively covering almost all such cases in Germany. A few similar cases have been filed in Italy.

Reuters reported:

Tobias Ulbrich, a lawyer at Rogert & Ulbrich, told Reuters he aimed to challenge in court the assessment made by European Union regulators and German vaccine assessment bodies that the BioNTech shot has a positive risk-benefit profile.

German pharmaceutical law states that makers of drugs or vaccines are only liable to pay damages for side-effects if “medical science” shows that their products cause disproportionate harm relative to their benefits or if the label information is wrong.

BioNTech, which holds the marketing authorisation in Germany for the shot it developed with Pfizer , said it concluded after careful consideration that the case was without merit.

“The positive benefit-risk profile of Comirnaty remains positive and the safety profile has been well characterised,” the biotech firm said, referring to the vaccine’s brand name.

It noted about 1.5 billion people had received the shot across the world, including more than 64 million in Germany.

The European Medicines Agency (EMA) also claimed that BioNTech’s Comirnaty, the most prevalent vaccine in the Western world, is “safe for use.”

EMA claimed that vaccines have helped save almost ’20 million lives globally’ in the first year of the pandemic alone. While acknowledging a ‘rare’ risk of myocarditis and pericarditis, two types of heart inflammation, primarily in young males post-vaccination, the EMA affirms that safety monitoring was not compromised during fast-track assessments.

Reuters reported that the liability issue remains uncertain, especially regarding who would pay legal costs or compensation if the plaintiff wins. EU’s bulk purchase agreements with vaccine manufacturers, including BioNTech-Pfizer, reportedly contain full or partial liability waivers for legal costs and potential compensation, which could force EU governments to bear some costs.

Germany, like many countries, has a no-fault compensation program for individuals who suffer permanent harm from vaccines. However, participation in this program does not preclude an individual from seeking damages separately.

In contrast, the United States has granted manufacturers immunity from liability for COVID vaccines receiving regulatory approval.

[rockislandadultreads]

Read-Alike Friday: In the Lives of Puppets by T.J. Klune

A Psalm for the Wild-Built by Becky Chambers

Centuries before, robots of Panga gained self-awareness, laid down their tools, wandered, en masse into the wilderness, never to be seen again. They faded into myth and urban legend.

Now the life of the tea monk who tells this story is upended by the arrival of a robot, there to honor the old promise of checking in. The robot cannot go back until the question of "what do people need?" is answered. But the answer to that question depends on who you ask, and how. They will need to ask it a lot. Chambers' series asks: in a world where people have what they want, does having more matter?

This is the first volume in the “Monk and Robot” series. 

Borne by Jeff VanderMeer

In a ruined, nameless city of the future, a woman named Rachel, who makes her living as a scavenger, finds a creature she names “Borne” entangled in the fur of Mord, a gigantic, despotic bear. Mord once prowled the corridors of the biotech organization known as the Company, which lies at the outskirts of the city, until he was experimented on, grew large, learned to fly and broke free. Driven insane by his torture at the Company, Mord terrorizes the city even as he provides sustenance for scavengers like Rachel.

At first, Borne looks like nothing at all—just a green lump that might be a Company discard. The Company, although severely damaged, is rumoured to still make creatures and send them to distant places that have not yet suffered Collapse. Borne somehow reminds Rachel of the island nation of her birth, now long lost to rising seas. She feels an attachment she resents; attachments are traps, and in this world any weakness can kill you. Yet when she takes Borne to her subterranean sanctuary, the Balcony Cliffs, Rachel convinces her lover, Wick, not to render Borne down to raw genetic material for the drugs he sells—she cannot break that bond.

Against his better judgment, out of affection for Rachel or perhaps some other impulse, Wick respects her decision. Rachel, meanwhile, despite her loyalty to Wick, knows he has kept secrets from her. Searching his apartment, she finds a burnt, unreadable journal titled “Mord,” a cryptic reference to the Magician (a rival drug dealer) and evidence that Wick has planned the layout of the Balcony Cliffs to match the blueprint of the Company building. What is he hiding? Why won’t he tell her about what happened when he worked for the Company?

This is the first volume in the “Borne” series. 

Anthropocene Rag by Alexander C. Irvine 

In the future United States, our own history has faded into myth and traveling across the country means navigating wastelands and ever-changing landscapes.

The country teems with monsters and artificial intelligences try to unpack their own becoming by recreating myths and legends of their human creators. Prospector Ed, an emergent AI who wants to understand the people who made him, assembles a ragtag team to reach the mythical Monument City.

In this nanotech Western, Alex Irvine infuses American mythmaking with terrifying questions about the future and who we will become.

Wanderers by Chuck Wendig

Shana wakes up one morning to discover her little sister in the grip of a strange malady. She appears to be sleepwalking. She cannot talk and cannot be woken up. And she is heading with inexorable determination to a destination that only she knows. But Shana and her sister are not alone. Soon they are joined by a flock of sleepwalkers from across America, on the same mysterious journey. And like Shana, there are other "shepherds" who follow the flock to protect their friends and family on the long dark road ahead.

For as the sleepwalking phenomenon awakens terror and violence in America, the real danger may not be the epidemic but the fear of it. With society collapsing all around them--and an ultraviolent militia threatening to exterminate them--the fate of the sleepwalkers depends on unraveling the mystery behind the epidemic. The terrifying secret will either tear the nation apart--or bring the survivors together to remake a shattered world.

This is the first volume in the “Wanderers” series. 

[clinfinitesolution1]

The Rising Influence of Contract Research Organizations in India

In recent years, Contract Research Organizations (CROs) have become indispensable in the pharmaceutical, biotechnology, and medical device industries, offering specialized services to enhance research and development processes. India, with its robust healthcare infrastructure, skilled workforce, and cost-effective services, has emerged as a key player in the CRO industry, attracting global pharmaceutical companies seeking quality research support.

The Growing Importance of Contract Research Organization In India

India has witnessed rapid growth in the Contract Research Organization sector, with more global pharmaceutical and biotech companies outsourcing research work to Indian CROs. The country’s diverse patient pool, advanced clinical trial facilities, and regulatory expertise make it an ideal destination for conducting clinical trials and medical research. As a result, Contract Research Organizations in India are increasingly becoming central to the global healthcare industry’s success.

Key Services Offered by Contract Research Organization In India

Contract Research Organizations In India provide a wide range of services that cater to various stages of drug development and medical research. These services include preclinical and clinical trial management, regulatory affairs, data management, and medical writing. CROs also handle pharmacovigilance (monitoring the safety of pharmaceutical products) and market access strategies, ensuring that new drugs and therapies meet global standards and reach the appropriate market efficiently.

Benefits of Choosing a Contract Research Organization In India

There are multiple reasons why international pharmaceutical companies are increasingly turning to Contract Research Organizations in India for their research needs. One of the key advantages is cost-effectiveness. Compared to Western countries, India offers competitive pricing for clinical trials and other research services, making it a budget-friendly alternative without compromising quality. Furthermore, Indian CROs have access to a large pool of highly skilled professionals who are trained in the latest research techniques and global regulatory requirements. This expertise, combined with a commitment to high standards, ensures efficient and successful project execution.

The Role of Contract Research Organization In India in Clinical Trials

Clinical trials form the cornerstone of the pharmaceutical industry, and Contract Research Organizations in India play a critical role in facilitating these trials. India’s advantages in conducting clinical trials include a large, diverse population with a wide range of health conditions, making it easier to recruit patients for trials. Additionally, CROs in India manage all phases of clinical trials, from planning and regulatory approval to data collection and analysis, helping pharmaceutical companies navigate complex regulatory environments and ensure compliance with international standards.

Regulatory Compliance and Quality Standards of Contract Research Organization In India

For pharmaceutical companies, compliance with international regulations is non-negotiable, and CROs in India are known for their commitment to maintaining high-quality standards. Indian CROs are well-versed in global regulatory frameworks, such as those set by the FDA, EMA, and ICMR. By adhering to strict guidelines, they ensure that clinical trials and research processes are executed with the utmost precision and in compliance with the highest quality standards, thereby increasing the likelihood of successful regulatory approvals.

Challenges Faced by Contract Research Organization In India

Despite the growth and success of CROs in India, there are several challenges that need to be addressed to maintain progress in the industry. Issues such as data security, competition among numerous CROs, and overcoming regulatory and infrastructural hurdles are significant concerns. Ensuring patient safety and maintaining confidentiality during clinical trials also remains a priority as the industry evolves.

The Future of Contract Research Organization In India

Looking ahead, the Contract Research Organization sector in India is poised for even more growth as global healthcare and research demands continue to rise. Technological advancements, such as artificial intelligence and machine learning, are reshaping clinical research, enabling faster data analysis and more precise results. Furthermore, Indian CROs are expanding their expertise into new therapeutic areas, including oncology, immunology, and gene therapy, to meet the demands of an ever-evolving global market.

Conclusion

In conclusion, Contract Research Organizations in India provide an unparalleled combination of expertise, cost efficiency, and global compliance that makes them an ideal partner for companies seeking to advance their research and development efforts. With a highly skilled workforce, regulatory expertise, and the ability to conduct complex clinical trials, CROs in India are poised to play an even larger role in shaping the future of global healthcare.

[healthlineonline]

You need Somastim for Sale for fast recovery from injury

Somastim is the best identical drug of naturally created human growth hormone. Adequate production and extraction processes are followed to produce the medicine properly and preserve the 3-D structure. The medicine is developed and tested effectively to conform to all the USAP regulations. You can easily have Somastim for Sale online from a reputed seller. You can also get valuable recommendations on dosage and the best way of treatment. For great benefits, you need to use it every year in particular cycles. This is best for achieving metabolic as well as anabolic impacts. For more details click:

https://sciroxxonline.com/domestic-supply-steroids-hgh-anabolics-and-ancillaries/245-hgh-somastim.html

[medicinemanufacturing]

India’s Pharmaceutical Industry: A Global Leader in Medicine Production

The pharmaceutical industry in India has become a powerhouse in the global healthcare landscape. Known for its robust manufacturing capabilities, affordable medicines, and a rapidly evolving R&D sector, India has cemented its position as a leading player in the global pharmaceutical market. With an annual growth rate of around 10%, this industry is poised for further expansion in the coming years.

An Overview of the Indian Pharmaceutical Industry

The Indian pharmaceutical sector is one of the largest and most rapidly growing in the world. It is ranked third globally by volume and 14th by value. In 2020, India was responsible for supplying around 40% of the global demand for generic medicines, 25% of the total medicines consumed in the UK, and nearly half of the demand for vaccines worldwide. This impressive scale can be attributed to the country’s advanced manufacturing capabilities, well-regulated market, and a strong focus on R&D.

India's pharmaceutical sector is primarily divided into two main segments: generic drugs and active pharmaceutical ingredients (APIs). The country is home to some of the world's largest producers of generic drugs, which are known for their affordability without compromising on quality. This makes India an essential supplier of medicines to both developed and developing nations.

Key Drivers Behind the Growth of the Pharmaceutical Industry in India

Cost-Effectiveness and Manufacturing Excellence One of the main reasons behind the success of the pharmaceutical industry in India is the cost-effectiveness of its production processes. The country is able to produce medicines at a fraction of the cost compared to Western countries, thanks to lower labor and manufacturing costs. This competitive edge has made Indian medicines highly sought after in both emerging and developed markets.

Government Support and Regulatory Framework The Indian government has played a vital role in shaping the pharmaceutical sector’s growth. The introduction of policies like the "Make in India" initiative, which encourages foreign investments in the domestic manufacturing sector, has created a favorable environment for industry expansion. Additionally, the National Pharmaceutical Pricing Authority (NPPA) ensures that essential medicines remain affordable, further contributing to the country’s growing pharmaceutical exports.

Research and Development (R&D) Advancements India is also investing heavily in R&D, with pharmaceutical companies focusing on new drug development, biotechnology, and biosimilars. The rise of clinical trials and advanced drug discovery is expected to boost the country’s pharmaceutical exports and market share. Indian pharmaceutical companies are also increasingly collaborating with global firms for joint ventures in the biotech space, further enhancing their capabilities.

Skilled Workforce The presence of a large pool of highly skilled scientists, engineers, and technicians has been a key factor in the success of India's pharmaceutical sector. Universities and research institutes in India are producing a significant number of qualified professionals who contribute to the innovation and growth of the pharmaceutical industry.

Global Impact of the Indian Pharmaceutical Industry

The pharmaceutical industry in India is a critical contributor to global healthcare. Indian companies supply high-quality medicines to countries around the world, including the United States, Europe, and emerging markets. The country’s dominance in the generic drug market has made it a key supplier for multinational pharmaceutical companies looking to source affordable treatments.

India’s pharmaceutical exports have grown significantly over the past few years, with the country being the world’s largest exporter of generic drugs. In fact, India’s exports are not just limited to generics; the country also exports bulk drugs, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. This is a testament to the country's strong manufacturing capabilities and adherence to international quality standards.

Moreover, India’s pharmaceutical companies have earned a reputation for their high-quality research and development, especially in areas like biotechnology and vaccines. The Indian pharmaceutical industry’s rapid response to the COVID-19 pandemic, including the production of vaccines and treatments, further highlighted its critical role in global public health.

Challenges Facing the Indian Pharmaceutical Industry

Despite its many successes, the pharmaceutical industry in India faces several challenges. Intellectual property rights (IPR) issues, regulatory hurdles, and rising competition from other low-cost producers are some of the obstacles that the industry must navigate. Additionally, the increasing pressure to comply with international quality standards, such as Good Manufacturing Practices (GMP), has led to higher production costs, potentially eroding the cost advantage of Indian manufacturers. Another challenge is the growing complexity of global markets. With the rise of personalized medicine, biologics, and advanced therapies, India’s pharmaceutical companies must adapt to new technologies and drug development practices to stay competitive.

The Future of the Pharmaceutical Industry in India

The future of the pharmaceutical industry in India looks promising, with several factors driving its growth. The Indian government has pledged to improve the healthcare system by increasing its budget for the sector and promoting the production of affordable medicines.

India’s pharmaceutical sector is also benefitting from its expanding healthcare infrastructure, rising middle-class income, and increasing life expectancy. As the demand for healthcare services rises, the pharmaceutical industry will play an even more significant role in ensuring access to affordable, quality medicines for the Indian population.

In addition, the focus on biotechnology, precision medicine, and vaccines is expected to drive innovation in the pharmaceutical sector, opening up new opportunities for Indian companies to compete globally. As India continues to improve its R&D capabilities and leverage its low-cost manufacturing advantages, the country will remain at the forefront of the global pharmaceutical market.

Conclusion

The pharmaceutical industry in India is on a trajectory of sustained growth, driven by a combination of cost advantages, a highly skilled workforce, and a commitment to innovation. India’s role as the “pharmacy of the world” will only become more pronounced in the coming years, as the country continues to produce affordable, high-quality medicines for global markets. With a strong foundation, a supportive regulatory environment, and ongoing investments in research and development, India is well-positioned to maintain its leadership in the global pharmaceutical sector for years to come.

[memotrends]

China's biotech R&D dominance is on the rise (MRK:NYSE)

Jan. 18, 2025 3:56 pm ETMerck & Co., Inc. (MRK) stock., AZN TitleGSK, NVS, RHHBY, NGO, LLY, NVSEF, RHHBF, ABBV, GCVRZ, SMMT, HNSPF, AKESFFrom: Dating Dulan, SA News Editor narvikk/E+ via Getty Images Amid growing geopolitical tensions between the United States and China, there are signs of growing deal-making activity between Western pharmaceutical companies and Chinese biotechs, several…

[credenceresearchdotblog]

The Prokaryotic Recombinant Protein Market is projected to grow from USD 2725.2 million in 2024 to an estimated USD 4278.42 million by 2032, with a compound annual growth rate (CAGR) of 5.8% from 2024 to 2032.The Prokaryotic Recombinant Protein Market has been experiencing significant growth, driven by advancements in biotechnology, expanding research in protein therapeutics, and increasing demand for cost-effective biologics production. Prokaryotic systems, particularly Escherichia coli (E. coli), have emerged as a preferred host for recombinant protein expression due to their simplicity, rapid growth, and ability to produce high yields. This article explores the key factors driving the market, challenges, applications, and future prospects.

Browse the full report at https://www.credenceresearch.com/report/prokaryotic-recombinant-protein-market

Market Drivers and Dynamics

Rising Demand for Biologics and Biosimilars Biologics, including monoclonal antibodies, vaccines, and enzymes, are critical in treating chronic diseases like cancer, diabetes, and autoimmune disorders. The production of recombinant proteins using prokaryotic systems is cost-effective and scalable, making it an attractive option for biosimilar development.

Technological Advancements in Recombinant Protein Production Continuous innovations in genetic engineering, such as CRISPR-Cas9 and synthetic biology, have improved the precision and efficiency of prokaryotic expression systems. Advanced tools for optimizing codon usage, promoters, and plasmids have significantly enhanced the expression of complex proteins.

Growing Biopharmaceutical Research and Development (R&D) The surge in R&D investments by pharmaceutical and biotech companies to develop novel therapies has fueled the demand for prokaryotic recombinant proteins. Research initiatives aimed at understanding disease pathways, drug discovery, and protein-protein interactions rely heavily on these proteins.

Applications in Diverse Sectors

Pharmaceutical and Therapeutics Prokaryotic recombinant proteins are widely used to produce therapeutic proteins such as insulin, growth hormones, and clotting factors. The affordability and scalability of prokaryotic systems make them indispensable for meeting the global demand for life-saving biologics.

Diagnostics The diagnostic industry uses recombinant proteins to develop enzyme-linked immunosorbent assays (ELISA), Western blotting, and other diagnostic tools. These proteins are essential for detecting infectious diseases, autoimmune disorders, and cancers.

Agriculture and Industrial Applications In agriculture, recombinant proteins are used to develop genetically modified crops with enhanced resistance to pests and diseases. Industrial enzymes produced in prokaryotic systems are employed in various industries, including food and beverage, textiles, and biofuels.

Challenges in the Market

Limitations in Post-Translational Modifications Prokaryotic systems lack the machinery for post-translational modifications, such as glycosylation, which are essential for the biological activity of certain therapeutic proteins. This limitation has restricted the use of prokaryotic systems for complex protein production.

Protein Misfolding and Aggregation High expression levels in prokaryotic systems can lead to misfolded or aggregated proteins, affecting their functionality. Overcoming these challenges requires optimizing culture conditions and using molecular chaperones.

Regulatory and Ethical Considerations The production of recombinant proteins must comply with stringent regulatory standards to ensure safety and efficacy. The ethical implications of genetic engineering also continue to be a topic of debate.

Future Prospects

The Prokaryotic Recombinant Protein Market is poised for continued growth, supported by advancements in synthetic biology, the integration of AI in protein design, and the development of hybrid systems that combine the strengths of prokaryotic and eukaryotic hosts. Moreover, the increasing focus on personalized medicine and precision therapies is likely to expand the market's applications.

Sustainability in protein production will also play a critical role. Efforts to reduce environmental impact, such as using renewable feedstocks and optimizing bioprocesses, will shape the market's trajectory.

Key Player Analysis:

Abnova Corporation

Batavia Biosciences

Bioclone

Cayman Chemical Company

Cusabio Technology

Eli Lilly and Company

Geltor IndieBio

Geno Technology

Kaneka and Eurogentec

Merck

Prospec Tany Technogene

Randox Laboratories

Roche

Segmentation:

By Product Type:

Hormones

Interferons

Interleukins

Others

By End-User/Application:

Biotechnology Companies

Research institutes

Contract Research organizations

Hospital

Laboratories

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/prokaryotic-recombinant-protein-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com 

[knmurthy]

Top Biotech Consultancy Services Provider In India

Top Biotech Consultancy Services Providers in India: A Comprehensive Guide

India’s biotechnology sector is experiencing rapid growth, emerging as a hub for research, development, and innovation. With advancements in genomics, pharmaceuticals, healthcare, and agriculture, biotech companies are shaping the future of global health and sustainability. However, navigating the complexities of the biotech world requires specialized knowledge and expertise. This is where biotech consultancy services come into play, offering crucial insights, strategic guidance, and operational support to companies looking to thrive in this dynamic field.

In this blog, we’ll take a look at the top biotech consultancy services in India and why these services are crucial for success in the biotechnology industry.

What Do Biotech Consultancy Services Offer?

Biotech consultancy firms in India offer a wide range of services designed to support the diverse needs of biotech companies. These services include:

Regulatory Affairs and Compliance: One of the most critical aspects of the biotech industry is navigating the complex regulatory landscape. Consultancy services guide firms through compliance with national and international regulations, ensuring that products meet safety, quality, and efficacy standards.

Market Research and Business Strategy: Biotech consultants provide in-depth market analysis to help companies identify new opportunities, understand market trends, and build effective business strategies that promote growth and profitability.

Technology Transfer and Licensing: With innovation being a cornerstone of biotechnology, consultancy firms assist businesses with the smooth transfer of technology, intellectual property, and licensing arrangements to foster collaboration and product development.

Clinical Trials and Product Development: Consultancy services help biotech firms design and implement clinical trials while offering advice on protocol development, data analysis, and regulatory submission. This ensures that the development of biotech products follows the best practices for efficacy and safety.

Research and Development (R&D) Support: Consultants can provide expertise in research methodologies, design, and laboratory management, supporting biotech companies with cutting-edge developments and innovation.

Investment and Funding Guidance: Many biotech startups struggle with securing adequate funding. Consultancy firms can help companies attract investors, develop funding strategies, and improve financial planning to sustain long-term growth.

Why Choose Biotech Consultancy Services in India?

Expertise in Biotechnology: India has a robust pool of talented professionals with deep knowledge in biotechnology, life sciences, and allied fields. Biotech consultancy services leverage this expertise to offer cutting-edge solutions and insights.

Cost-Effective Solutions: Compared to their counterparts in Western countries, biotech consultancy firms in India provide high-quality services at competitive prices, offering cost-effective solutions to both startups and established companies.

Access to a Thriving Biotech Ecosystem: India’s rapidly growing biotech industry offers numerous opportunities for companies. Consultants are well-positioned to help businesses tap into these opportunities by connecting them with industry players, regulatory bodies, and funding sources.

Global Reach with Local Knowledge: Many consultancy firms in India have an international perspective, understanding both local and global market dynamics. This allows them to provide valuable advice for biotech companies that are planning to expand beyond Indian borders.

Key Areas Where Consultancy Firms Make a Difference

Precision Medicine: Precision medicine is a revolutionary concept in healthcare, and India’s biotech consultants are helping businesses develop and market therapies tailored to individual genetic profiles. They offer expertise in clinical trials, genetic testing, and personalized treatments.

Biopharmaceuticals: India has become a global leader in biopharmaceuticals, and consultants in this area provide critical support for drug development, commercialization, and navigating regulatory approvals.

Agricultural Biotechnology: With agriculture playing a vital role in India’s economy, consultants in agricultural biotech offer services to improve crop yields, pest control, and sustainable farming practices using advanced biotechnological techniques.

Health & Wellness Biotech: Consultants are also helping businesses in the growing field of health & wellness biotechnology, guiding companies in developing nutraceuticals, functional foods, and wellness products.

Conclusion: Unlocking Growth with Biotech Consultancy Services

The future of biotechnology in India is promising, with new advancements being made in areas like genomics, pharmaceuticals, agriculture, and health. To keep up with the fast-paced changes in this sector, biotech companies require specialized knowledge, strategic direction, and operational support. Biotech consultancy services in India provide the expertise, resources, and market insights necessary to help companies navigate challenges, seize opportunities, and grow in a competitive global landscape.

As the biotech industry continues to evolve, the role of consultancy firms in fostering innovation and guiding businesses to success will only become more crucial. Companies that tap into the expertise of these firms are better positioned to thrive, deliver groundbreaking products, and contribute to the advancement of biotechnology worldwide.

URL: For more information, visit Pharma-Consultant : Top Biotech Consultancy Services Providers in India

[global-research-report]

Aptamers Market Growth: Key Trends, Opportunities & Forecast

The global aptamers market size is expected to reach USD 10.88 billion by 2030, according to a new report by Grand View Research Inc. The market is expected to expand at a CAGR of 24.54% from 2023 to 2030.  The growth of the market is attributed to the strong presence of product pipelines and their expected launch during the forecast period. Some of the products in the pipeline are E10030 (Fovista), ARC1905 (Zimura) by IVERIC Bio, Inc., AGRO100 by Antisoma Research Ltd, NOX-A12 (olaptesed pegol) & NOX-E36 (emapticap pegol) by NOXXON Pharma, and NU172 by ARCA Biopharma, Inc. AGRO100 completed the phase 1 clinical trial for multiple oncology indications such as non-small cell lung cancer, solid tumors, and renal cancer.

In addition, initiatives undertaken by regulatory agencies such as the U.S. FDA, Health Canada, EMA, COFEPRIS, MHRA, and CDSCO to support the research and development in the field of aptamers are projected to fuel market growth. For instance, in March 2020, IVERIC Bio, Inc. received Fast Track designation from the U.S. FDA for Zimura for the treatment of patients with GA secondary to age-related macular degeneration (AMD). Zimura is a chemically synthesized pegylated RNA aptamer, administered by intravitreal injection. It acts by inhibiting complement factor C5 which is responsible for the development of AMD.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Companies are studying aptamers for applications such as western blotting, ELISA, therapeutics, and flow cytometry. Custom aptamer selection is considered to be an important service offered by existing aptamer players to life sciences companies. Thrombin aptamers, cocaine aptamers, and theophylline aptamers are some of the most frequently used customized aptamers for research and development activities. Thus, the surge in numbers of biotech and pharma companies working on research related to aptamers and related technologies has opened up new avenues for the growth of this market.

Moreover, there are a number of strategic initiatives undertaken by key players such as mergers & acquisitions, with an aim to expand their current aptamer product portfolio. For instance, in May 2022, Epicore Biosystems acquired Eccrine Systems' intellectual property and assets. This acquisition boosts Epicore’s wearable microfluidic solutions with additional aptamer-based sweat sensor technology from the Eccrine Systems and the University of Cincinnati to its aptamer product portfolio and strengthens the company’s position in the market. This aptamers-based sensor has been demonstrated in stress, pain, and other healthcare management applications.

Browse through Grand View Research's Biotechnology Industry Research Reports.

The global DNA diagnostics market sizewas estimated at USD 10.61 billion in 2024 and is projected to grow at a CAGR of 8.7% from 2025 to 2030.

The global CRISPR and Cas genes market sizewas estimated at USD 4.69 billion in 2024 and is projected to grow at a CAGR of 16.12% from 2025 to 2030.

Aptamers Market Segmentation

Grand View Research has segmented the global aptamers market on the basis of type, application, and region:

Aptamers Type Outlook (Revenue, USD Million; 2018 - 2030)

Nucleic Acid Aptamer

Peptide Aptamer

Aptamers Application Outlook (Revenue, USD Million; 2018 - 2030)

Diagnostics

Therapeutics

Research & Development

Others

Aptamers Regional Outlook (Revenue, USD Million; 2018 - 2030)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

MEA

South Africa

Saudi Arabia

UAE

Kuwait

Key Companies profiled:

SomaLogic

Aptamer Group

Aptadel Therapeutics

Base Pair Biotechnologies

Noxxon Pharma

Vivonics Inc.

Aptagen, LLC

TriLink Biotechnologies

Altermune LLC

AM Biotechnologies

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.